查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561421

2024-2032 年按产品（口服避孕药、子宫内避孕器、注射避孕药、阴道环等）、荷尔蒙、年龄层、最终用户和地区分類的荷尔蒙避孕市场报告

Hormonal Contraceptive Market Report by Product (Oral Contraceptive Pills, Intrauterine Device, Injectable Birth Control, Vaginal Rings, and Others), Hormone, Age Group, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球荷尔蒙避孕药市场IMARC Group达到187亿美元。在全球生殖健康和计划生育意识、妇女赋权不断增强（特别是在发展中地区）以及全球对避孕药具的接受和使用不断增加的推动下，该市场正在稳步增长。

荷尔蒙避孕药市场分析：

  • 主要市场驱动因素：对荷尔蒙避孕药的需求是由全球范围内的计划生育要求和接受程度所推动的。各国政府和非政府组织仅仅致力于降低意外怀孕率，导致了这个市场的成长。
  • 主要市场趋势：根据荷尔蒙避孕药市场预测，近期对该市场产生重大影响的趋势是长效可逆避孕药（包括子宫内避孕器和埋植剂）的消费增加，因为其更有效且作用时间更长。
  • 地理趋势：由于较高的意识水平、收入和医疗设施，北美和西欧在荷尔蒙避孕药的使用方面主要处于领先地位。相反，由于城市化、医疗保健支出和生活方式因素，预计亚太地区将成长最快。
  • 竞争格局：根据荷尔蒙避孕药市场研究，荷尔蒙避孕药市场有几家大型製药公司，拥有广泛的产品组合和分销网络。小型和大型公司都在增加研发 (R&D) 活动的预算拨款，以开发副作用最小的新药，同时保持消费者便利。
  • 挑战与机会：虽然各个地理区域存在的文化阻力和监管障碍限制了市场成长，但仍有多种投资个人化避孕解决方案的机会，并关注女性就业增加的未解决的新兴市场。

荷尔蒙避孕药市场趋势：

提高全球生殖健康意识与教育

荷尔蒙避孕药在全球的广泛使用很大程度上取决于生殖健康意识和教育的提高。各国政府和世界卫生组织等相关国际组织不断宣传透过安全有效避孕措施实施计划生育的理念和优势。根据世界卫生组织统计，到2021年，全球有19亿育龄妇女，其中11亿需要计划生育。其中，8.74亿人正在使用现代避孕方法，还有1.64亿名女性的避孕需求未被满足。因此，这极大地影响了荷尔蒙避孕药市场的收入。具体来说，广泛的全球运动针对女性和男性，让他们了解控制怀孕的能力以及减少人口快速增长的有效方法。此外，还推出了许多针对青少年和年轻人的教育计划，为以后的生活中明智的计划生育决策奠定基础。这些教育措施只有辅以医疗保健服务和咨询，使个人能够区分各种荷尔蒙避孕方法，才能发挥作用。在这方面，全面的全球教育和健康计画对于确保这些产品在不同地区得到使用是必不可少的。

技术进步与产品创新

新的、更好的荷尔蒙避孕选择的开发彻底改变了这个领域，也推动了荷尔蒙避孕的市场价值。最近，一种新型超低剂量製剂（20 μg EE 和 3 mg DRSP）已以 24/4 方案上市（Yaz；Bayer AG）。其功效与较旧的 COC 相似，甚至更好，出血模式是可以接受的。此外，药物传输系统的开发正在产生更可靠的产品，更易于管理并产生更少的副作用。延长週期的避孕药和子宫内避孕器的改进，例如更少的健康危害和更长的使用期限，都满足了消费者对便利性和生活方式相容性日益增长的需求。此外，这些进步增强了消费者体验和依从性，从而扩大了市场，因为女性更有可能使用和恢復使用避孕药具。此外，避孕产品技术的创新利用消费者获得的兴趣、采用和市场选择来引入更精细的技术。因此，这正在创造积极的荷尔蒙避孕市场前景。

计划生育的政策措施和资金

政府支持政策和增加计划生育项目资金等政策促进了荷尔蒙避孕市场的成长。一些地区的政府，特别是发展中国家的政府，已经通过了政策，确保个人能够获得避孕药具，作为公共卫生和妇女赋权措施的一部分。这些政策降低了避孕药具的成本，使生殖健康服务变得全面并为每个人提供，并将避孕教育纳入公共卫生运动。此外，全球财团和机构提供资金帮助服务不足的地区获得生殖健康服务。所有这些措施都旨在降低成本并说服个人获得避孕药具。确保轻鬆、低价地取得荷尔蒙避孕药具的政策有助于满足公共卫生需求和其他社会经济目标。

荷尔蒙避孕药市场区隔：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品、荷尔蒙、年龄层和最终用户对市场进行了分类。

按产品划分：

  • 口服避孕药
  • 子宫内避孕器 (IUD)
  • 注射避孕药
  • 阴道环
  • 其他的

口服避孕药占据了荷尔蒙避孕药市场的大部分份额

该报告根据产品提供了详细的市场细分和分析。这包括口服避孕药、子宫内避孕器 (IUD)、注射避孕药、阴道环等。报告称，口服避孕药占了最大的份额。

口服避孕药 (OCP) 因其无与伦比的功效、便利性和可用性组合，继续引领荷尔蒙避孕药市场，成为最大的产品领域。荷尔蒙避孕药市场概况表明，由于其安全性，避孕药是全球最常见的避孕方法，可确保可预测和可靠的计划生育。除了可靠性之外，这些产品的市场还因配方的多样性而多样化，药丸有组合版本和纯黄体素版本，反映了医疗和消费者的偏好。此外，市场趋势取决于 OCP 与其他长期荷尔蒙结合避孕药相比的价格，以及基于 OCP 长期使用历史的记录的便利性，儘管有副作用，但仍然安全。同时，该领域仍在发展中，许多新的选择已经并将继续开发，以减少副作用并提高荷尔蒙製剂的安全性和舒适性。整体而言，避孕 OCP 仍然是全世界妇女生殖健康的前提。

荷尔蒙分解：

  • 仅含黄体素的避孕药
  • 复方荷尔蒙避孕药

复方荷尔蒙避孕药产业份额最大

荷尔蒙避孕药市场研究报告还提供了基于荷尔蒙的详细市场细分和分析。这包括纯孕激素避孕药和合併荷尔蒙避孕药。报告称，复方荷尔蒙避孕药占据了最大的市场份额。

荷尔蒙细分市场以复方荷尔蒙避孕药（CHC）为主。促成该细分市场高份额的主要因素是其极高的避孕功效以​​及显着的健康益处。在有益效果中，值得一提的是保证月经週期的持续时间和月经的严重程度、预防卵巢囊肿以及显着降低子宫内膜癌的风险。 CHC 有丸剂、阴道环和贴片形式，让使用者可以选择最方便的给药方式。因此，CHC 由于其极大的灵活性和额外的健康益处，对广大用户来说是一个有吸引力的选择。在这些担忧中，一些临床医生提到了情绪障碍的风险和体重增加的可能性。然而，持续的改进旨在降低这些副作用的风险，并提高使用者满意度和依从性。

按年龄组别划分：

  • 15-24岁
  • 25-34岁
  • 35-44岁
  • 44岁以上

15-24岁代表主导细分市场

该报告根据年龄组对市场进行了详细的细分和分析。这包括 15-24 岁、25-34 岁、35-44 岁以及 44 岁以上。报告显示，15-24岁年龄层是最大的族群。

根据已确定的人口分布和社会特征趋势，15-24 岁群体是荷尔蒙避孕药使用者的最大群体。这个年龄范围通常指青春期后期和成年早期，这是个人最积极探索和利用避孕方法作为其性健康和生殖健康管理常规的一部分的时期。此外，该细分市场的大幅增长是由于青少年和年轻人性活动的增加，以及教授安全性行为和促进避免意外怀孕的广泛教育计划的支持。因此，这也对荷尔蒙避孕药市场统计数据产生正面影响。教育机构、医疗保健提供者和社区组织特别关注这个年龄段，进行各种外展活动和咨询，让人们更容易获得有关不同避孕方法的资讯。同样，在组建家庭之前建立职业或完成教育的愿望也鼓励这些年轻人寻求充足、安全和可靠的避孕选择，从而为该子市场的强大代表性做出了重大贡献。

按最终用户划分：

  • 医院和诊所
  • 居家护理
  • 门诊手术中心
  • 其他的

居家照护在市场上表现出明显的主导地位

报告还提供了基于最终用户的详细市场细分和分析。这包括医院和诊所、家庭护理、门诊手术中心等。报告显示，家庭护理占据了最大的市场份额。

荷尔蒙避孕药市场的主要最终用户是家庭护理领域，这得益于其提供的便利性和隐私性。鑑于当前消费者要求在舒适的家中做出医疗保健决定的趋势，对可自我管理的产品的需求必然会增加。避孕药具比以往任何时候都更容易获得，这一事实进一步促进了这一趋势。例如，口服药丸、透皮贴片和阴道环现在无需任何人的帮助即可使用，并且在世界大部分地区的市场上都很容易买到。根据荷尔蒙避孕药市场分析，许多线上平台和远距医疗服务使获得这些产品变得容易，从而增强了在家中管理避孕需求的吸引力。此外，家庭护理趋势与以消费者为中心的医疗保健的整体发展相对应，个人在满足其健康需求时寻求最佳水平的便利性、保密性和自主性。这些因素大大改变了荷尔蒙避孕药市场的动态。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美市场领先，占据最大的荷尔蒙避孕药市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是荷尔蒙避孕药最大的区域市场。

从地理位置上看，北美是全球荷尔蒙避孕药的领先市场，因为该地区拥有发达的医疗基础设施、对避孕药具类型的高度认识以及政府的大力支持。北美还有几家领先的製药公司投资开发更方便、有效、安全的避孕药。同时，美国人的保健文化最为发达，他们更喜欢提前「吞下」口服药物，而不是子宫内螺旋。此外，许多类型的避孕药具都包含在保险范围内，包括保单，这提高了可近性。公共和私人组织提供的许多教育计画也宣传使用避孕药具的好处。这种全面的支持确保北美不仅是一个大市场，而且是全球荷尔蒙避孕领域的领先地区。

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

荷尔蒙避孕药市场的主要参与者致力于资助研究并提高其产品的功效和安全性。它们不断减少副作用并提高用户便利性，以获得市场认可并保持品质领先地位。此外，包括拜耳公司、辉瑞公司和默克在内的公司希望透过在发展中国家的收购和联盟来扩大其全球影响力，而这些国家目前对荷尔蒙避孕药的需求较高。此外，製造商经常宣传荷尔蒙避孕，并向更多女性宣传相关优势。这些进展支持发展目标，同时有助于实现更全面的公共卫生政策目标。

荷尔蒙避孕药市场新闻：

  • 2024 年 4 月 25 日：默克公司发表声明，将投资超过 3 亿欧元（3.208 亿美元）在德国达姆施塔特的总部建立一个新的生命科学研究中心。
  • 2022年1月10日：Agile Therapeutics, Inc.宣布与Afaxys Pharma, LLC建立新的合作伙伴关係，以支持Twirla(R)左炔诺孕酮和炔雌醇透皮系统的推广。

本报告回答的关键问题：

  • 迄今为止，全球荷尔蒙避孕药市场表现如何，未来几年将如何表现？
  • 全球荷尔蒙避孕药市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球荷尔蒙避孕药市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的荷尔蒙避孕市场？
  • 基于产品的市场区隔是什么？
  • 荷尔蒙避孕市场上最具吸引力的产品是什么？
  • 基于荷尔蒙的市场区隔是什么？
  • 荷尔蒙避孕药市场上最具吸引力的荷尔蒙是什么？
  • 市场按年龄层划分是怎样的？
  • 荷尔蒙避孕药市场中哪个年龄最具吸引力？
  • 基于最终用户的市场区隔是什么？
  • 荷尔蒙避孕药市场中哪一个对最终用户最具吸引力？
  • 市场竞争结构如何？
  • 全球荷尔蒙避孕药市场的主要参与者/公司有哪些？

本报告回答的关键问题：

  • 迄今为止，全球荷尔蒙避孕药市场表现如何，未来几年将如何表现？
  • 全球荷尔蒙避孕药市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球荷尔蒙避孕药市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的荷尔蒙避孕市场？
  • 基于产品的市场区隔是什么？
  • 荷尔蒙避孕市场上最具吸引力的产品是什么？
  • 基于荷尔蒙的市场区隔是什么？
  • 荷尔蒙避孕药市场上哪种荷尔蒙最有吸引力？
  • 市场按年龄层划分是怎样的？
  • 荷尔蒙避孕药市场中哪个年龄最具吸引力？
  • 基于最终用户的市场区隔是什么？
  • 荷尔蒙避孕药市场上哪一个对最终用户最具吸引力？
  • 市场竞争结构如何？
  • 全球荷尔蒙避孕药市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球荷尔蒙避孕药市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 口服避孕药
    • 市场趋势
    • 市场预测
  • 子宫内避孕器 (IUD)
    • 市场趋势
    • 市场预测
  • 注射避孕药
    • 市场趋势
    • 市场预测
  • 阴道环
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依激素

  • 仅含黄体素的避孕药
    • 市场趋势
    • 市场预测
  • 复方荷尔蒙避孕药
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依年龄段

  • 15-24岁
    • 市场趋势
    • 市场预测
  • 25-34岁
    • 市场趋势
    • 市场预测
  • 35-44岁
    • 市场趋势
    • 市场预测
  • 44岁以上
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 医院和诊所
    • 市场趋势
    • 市场预测
  • 居家护理
    • 市场趋势
    • 市场预测
  • 门诊手术中心
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Afaxys Inc.
    • Agile Therapeutics Inc.
    • Allergan Inc. (AbbVie Inc.)
    • Bayer AG
    • Cipla Limited
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Piramal Group
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112024A4403

The global hormonal contraceptive market size reached US$ 18.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The market is experiencing steady growth driven by global awareness of reproductive health and family planning, the rising empowerment of women, particularly in developing regions, and the growing acceptance and use of contraceptives across the globe.

Hormonal Contraceptive Market Analysis:

  • Major Market Drivers: The demand for hormonal contraceptives is driven by family planning requirements and acceptance across the globe. The various governments and non-governmental organizations that solely try to reduce the rate of unplanned pregnancies are leading to the growth of this market.
  • Key Market Trends: According to the hormonal contraceptive market forecast, the recent trend that will have a major impact on this market is the increasing consumption of long-acting reversible contraceptives including IUDs and implants on account of being more effective and longer action period.
  • Geographical Trends: North America and Western Europe majorly lead in hormonal contraceptive usage due to high awareness levels, income, and healthcare facilities. On the contrary, Asia Pacific is anticipated to grow fastest due to urbanization, healthcare expenditure, and lifestyle factors.
  • Competitive Landscape: According to the hormonal contraceptive market research, the hormonal contraceptives market has several big pharmaceutical companies with extensive product portfolios and distribution networks. Both small and large companies are increasing their budgetary allocation to research and development (R&D) activities to develop new drugs with minimal side effects while maintaining consumer convenience.
  • Challenges and Opportunities: While the existence of cultural resistance and regulatory hurdles in various geographical areas constrain market growth, there remain multiple opportunities to invest in personalized contraceptive solutions and focus on unaddressed emerging markets with an increase in female employment.

Hormonal Contraceptive Market Trends:

Increasing global awareness and education on reproductive health

The extensive utilization of hormonal contraceptives on a global scale is largely dependent on increased awareness and education about reproductive health. Governments and relevant international organizations, such as the World Health Organization, continuously promote the concept and advantages of family planning through safe and effective contraceptive use. According to the World Health Organization, there were 1.9 billion women of reproductive age worldwide in 2021, 1.1 billion of whom need family planning. Of these, 874 million are using modern contraceptive methods, and there are 164 million women with an unmet need for contraception. Thus, this is significantly influencing the hormonal contraceptive market revenue. Specifically, extensive global campaigns target both women and men, informing them about their ability to control pregnancies and effective ways to reduce rapid population growth. Moreover, numerous educational programs targeting teens and young individuals have been rolled out to lay the groundwork for well-informed family planning decisions later in life. These educational initiatives are only effective when complemented by access to healthcare services and consultations that enable individuals to differentiate among various hormonal contraceptive methods. In this regard, comprehensive global educational and health programs are indispensable in ensuring these products are taken up in different regions.

Technological advancements and product innovation

The development of new and better hormonal contraceptive options that revolutionize the area also propels hormonal contraceptive market value. Recently, a novel ultra-low-dose preparation of 20 μg EE and 3 mg DRSP has been marketed in a 24/4 regimen (Yaz; Bayer AG). The efficacy is similar to, if not better than, older COCs, and the bleeding pattern is acceptable. Additionally, drug delivery system development is resulting in more reliable items that are simpler to manage and produce fewer side effects. Extended-cycle pills and improvements to intrauterine devices, such as fewer health hazards and a longer period of utilization, respectively, all address the increasing need for consumer convenience and lifestyle compatibility. In addition, such advancements enhance the consumer experience and compliance, resulting in an expanded market since women are more likely to use and resume contraceptive use. In addition, innovations in contraceptive product technologies take advantage of consumers' acquired interest and adoption and market choice to introduce more refined technologies. Therefore, this is creating a positive hormonal contraceptive market outlook.

Policy initiatives and funding for family planning

Policies, such as supportive government policies and increased funding for family planning programs, facilitate the hormonal contraceptive market growth. Several governments in various regions, particularly in developing countries, have passed policies to ensure that individuals have access to contraceptives as part of public health and women's empowerment measures. These policies lower the cost of contraceptives, make reproductive health services comprehensive and available to everyone, and incorporate contraceptive education in public health campaigns. Furthermore, global consortia and institutions offer funding to help underserved areas access reproductive health services. All these measures seek to reduce the cost and convince individuals to get contraceptives. Policies that guarantee easy and low-priced access to hormonal contraceptives help to meet public health needs and other socio-economic targets.

Hormonal Contraceptive Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, hormone, age group, and end user.

Breakup by Product:

  • Oral Contraceptive Pills
  • Intrauterine Device (IUD)
  • Injectable Birth Control
  • Vaginal Rings
  • Others

Oral contraceptive pills account for the majority of the hormonal contraceptive market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes oral contraceptive pills, intrauterine device (IUD), injectable birth control, vaginal rings, and others. According to the report, oral contraceptive pills represented the largest segment.

Oral contraceptive pills (OCPs) continue to lead the hormonal contraceptive market as the largest product segment due to their unmatched combination of efficacy, convenience, and availability. The hormonal contraceptive market overview suggests that pills are the most common contraceptive method worldwide due to their safety, which secures predictable and reliable family planning. In addition to their reliability, the market for these products is diversified by the variability of formulations, with pills available in combined and progestin-only versions that reflect medical and consumer preferences. Moreover, the market tendency is determined by the price of OCPs in comparison with other long-term hormone-conjugated contraceptives, and the ease of documentation based on the long history of using OCPs that, despite the side effects, remain safe. In confluence with this, the segment is still developing, and many new options have been and continue to be developed to reduce the side effects and enhance the safety and comfort of hormonal formulations. Overall, contraceptive OCPs remain the premise of reproductive health for women worldwide.

Breakup by Hormone:

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

Combined hormonal contraceptive holds the largest share of the industry

A detailed breakup and analysis of the market based on the hormone have also been provided in the hormonal contraceptive market research report. This includes progestin-only contraceptive and combined hormonal contraceptive. According to the report, combined hormonal contraceptive accounted for the largest market share.

The hormone sub-segment is dominated by combined hormonal contraceptives (CHCs). The main factor contributing to the segment's high share is their very high contraceptive efficacy combined with significant health benefits. Among the beneficial effects, it is worth mentioning the guaranteed duration of the menstrual cycle and the severity of menstruation, the prevention of ovarian cysts, and the significant reduction in the risk of endometrial cancer. CHCs are available in the form of pills, vaginal rings, and patches, giving users an additional choice of the form of administration that is most convenient for them. Thus, CHCs are an attractive option for a wide range of users due to their great flexibility and additional health benefits. Among the concerns, some clinicians mention the risk of mood disorders and the likelihood of weight gain. However, ongoing improvements aim to decrease the risk of these side effects, enhancing user satisfaction and adherence.

Breakup by Age Group:

  • 15-24 Years
  • 25-34 Years
  • 35-44 Years
  • Above 44 Years

15-24 years represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the age group. This includes 15-24 years, 25-34 years, 35-44 years, and above 44 years. According to the report, 15-24 years represented the largest segment.

The group of 15-24 years stands out as the largest segment of hormonal contraceptive users, based on identified trends in demographic distribution and social peculiarities. This age range usually refers to late adolescence and young adulthood, a period when individuals are most active in exploring and utilizing contraceptive options as part of their sexual and reproductive health management routines. In addition, the segment's considerable growth is driven by increased sexual activity among adolescents and young individuals, supported by broad educational programs that teach safe sex and promote the avoidance of unplanned pregnancies. Thus, this is also positively influencing the hormonal contraceptive market statistics. Educational institutions, healthcare providers, and community organizations pay special attention to this age group, conducting various outreach activities and consultations to make information about different methods of contraception more accessible. Similarly, the desire to build a career or complete education before starting a family also encourages these young individuals to seek adequate, secure, and reliable contraceptive options, contributing significantly to the strong representation of this submarket.

Breakup by End User:

  • Hospitals and Clinics
  • Homecare
  • Ambulatory Surgical Centers
  • Others

Homecare exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and clinics, homecare, ambulatory surgical centers, and others. According to the report, homecare accounted for the largest market share.

The leading end-user in the hormonal contraceptive market is the homecare segment, driven by the convenience and privacy it offers. Given the current trend of consumers demanding to make their healthcare decisions from the comfort of their homes, the demand for products that can be self-administered was bound to increase. This trend is further facilitated by the fact that contraceptives have become more attainable than ever before. Oral pills, transdermal patches, and vaginal rings, for example, can now be utilized without anyone's help and are readily available on the market in most parts of the world. According to the hormonal contraceptive market analysis, many online platforms and telehealth services make access to these products easy, enhancing the appeal of managing contraceptive needs at home. Furthermore, the homecare trend corresponds to the overall developments in consumer-centered healthcare, whereby individuals are seeking optimal levels of convenience, confidentiality, and autonomy in attending to their health needs. These factors have significantly altered the dynamics within the hormonal contraceptive market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest hormonal contraceptive market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hormonal contraceptive.

Geographically, North America is the leading market for hormonal contraceptives globally due to the region's well-developed healthcare infrastructure, high awareness about contraceptive types, and strong government support. There are also several leading pharmaceutical companies in North America investing in the development of more convenient, effective, and safe contraceptives. At the same time, Americans are the most developed in terms of the culture of taking care of their health and they prefer to "swallow" an oral agent in advance rather than an intrauterine spiral. Additionally, many types of contraceptives are covered by insurance, including under policies, which enhance accessibility. Numerous educational programs provided by public and private organizations also inform about the benefits of using contraceptives. This comprehensive support ensures that North America is not only a large market but also a leading region in the global hormonal contraceptive space.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the hormonal contraceptive industry include:

  • Afaxys Inc.
  • Agile Therapeutics Inc.
  • Allergan Inc. (AbbVie Inc.)
  • Bayer AG
  • Cipla Limited
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Piramal Group
  • Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major players in the hormonal contraceptive market are committed to funding research and enhancing the efficacy and safety of their products. They consistently reduce side effects and increase user convenience to gain market acceptance and keep quality leadership. Furthermore, firms including Bayer AG, Pfizer, and Merck & Co. want to extend their global footprint through acquisitions and alliances in developing countries, where the hormonal contraceptive demand is currently higher. Additionally, manufacturers frequently promote hormonal contraception and educate more women about the advantages associated. These developments support development goals while aiding more comprehensive public health policy goals.

Hormonal Contraceptive Market News:

  • April 25, 2024: Merck & Co. Inc. makes a statement of investing over €300m ($320.8m) to establish a new Life Science Research Center at its main office located in Darmstadt, Germany.
  • January 10, 2022: Agile Therapeutics, Inc. announced that it has entered into a new partnership with Afaxys Pharma, LLC to support the promotion of the Twirla(R) levonorgestrel and ethinyl estradiol transdermal system.

Key Questions Answered in This Report:

  • How has the global hormonal contraceptive market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hormonal contraceptive market?
  • What is the impact of each driver, restraint, and opportunity on the global hormonal contraceptive market?
  • What are the key regional markets?
  • Which countries represent the most attractive hormonal contraceptive market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the hormonal contraceptive market?
  • What is the breakup of the market based on the hormone?
  • Which is the most attractive hormone in the hormonal contraceptive market?
  • What is the breakup of the market based on the age group?
  • Which is the most attractive age group in the hormonal contraceptive market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the hormonal contraceptive market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hormonal contraceptive market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hormonal Contraceptive Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Oral Contraceptive Pills
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intrauterine Device (IUD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Injectable Birth Control
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vaginal Rings
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Hormone

  • 7.1 Progestin-only Contraceptive
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combined Hormonal Contraceptive
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 15-24 Years
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 25-34 Years
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 35-44 Years
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Above 44 Years
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Ambulatory Surgical Centers
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Afaxys Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agile Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Allergan Inc. (AbbVie Inc.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Bayer AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Cipla Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Piramal Group
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Teva Pharmaceutical Industries Ltd
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hormonal Contraceptive Market: Major Drivers and Challenges
  • Figure 2: Global: Hormonal Contraceptive Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hormonal Contraceptive Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hormonal Contraceptive Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Hormonal Contraceptive Market: Breakup by Hormone (in %), 2023
  • Figure 6: Global: Hormonal Contraceptive Market: Breakup by Age Group (in %), 2023
  • Figure 7: Global: Hormonal Contraceptive Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Hormonal Contraceptive Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hormonal Contraceptive (Injectable Birth Control) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hormonal Contraceptive (Injectable Birth Control) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hormonal Contraceptive (Vaginal Rings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hormonal Contraceptive (Vaginal Rings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hormonal Contraceptive (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hormonal Contraceptive (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Hormonal Contraceptive (15-24 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Hormonal Contraceptive (15-24 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Hormonal Contraceptive (25-34 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Hormonal Contraceptive (25-34 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Hormonal Contraceptive (35-44 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Hormonal Contraceptive (35-44 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Hormonal Contraceptive (Above 44 Years) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Hormonal Contraceptive (Above 44 Years) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Hormonal Contraceptive (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Hormonal Contraceptive (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Hormonal Contraceptive (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Hormonal Contraceptive (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Hormonal Contraceptive (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Hormonal Contraceptive (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia-Pacific: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia-Pacific: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Hormonal Contraceptive Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Hormonal Contraceptive Market: Breakup by Country (in %), 2023
  • Figure 87: Middle East and Africa: Hormonal Contraceptive Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Global: Hormonal Contraceptive Industry: SWOT Analysis
  • Figure 89: Global: Hormonal Contraceptive Industry: Value Chain Analysis
  • Figure 90: Global: Hormonal Contraceptive Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hormonal Contraceptive Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hormonal Contraceptive Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Hormonal Contraceptive Market Forecast: Breakup by Hormone (in Million US$), 2024-2032
  • Table 4: Global: Hormonal Contraceptive Market Forecast: Breakup by Age Group (in Million US$), 2024-2032
  • Table 5: Global: Hormonal Contraceptive Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Hormonal Contraceptive Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Hormonal Contraceptive Market: Competitive Structure
  • Table 8: Global: Hormonal Contraceptive Market: Key Players